Most Read Articles
29 Nov 2017
Rapid onset opioids may allow for more effective treatment of breakthrough cancer pain as their pharmacokinetic profile closely mimics the pain’s time course
Christina Lau, 22 Oct 2015
A 21-gene expression assay can identify patients with early-stage breast cancer who can skip adjuvant chemotherapy without facing an increased risk of recurrence at 5 years.
Cathy Chow, PhD, 27 Aug 2015

HER2-positive breast cancer tends to be more aggressive, has worse patient prognosis, and responds less to treatment. A two-pronged approach to block the HER pathway via pertuzumab (Perjeta®, Roche), a first-in-class HER dimerization inhibitor, in combination with trastuzumab and chemotherapy, may offer more treatment options for HER2-positive metastatic breast cancer patients as well as those with early breast cancer. 

Saras Ramiya, 25 Oct 2017
The first patient-reported outcomes study on durvalumab treatment after chemoradiation in locally advanced non-small cell lung cancer (NSCLC) shows patients’ quality of life is similar to that of the patients who received placebo.

PRRT may improve survival in metastatic paraganglioma, pheochromocytoma

28 Sep 2017

Use of peptide receptor radionuclide therapy (PRRT) results in valuable clinical and biochemical responses with low toxicity and encouraging survival in unresectable paraganglioma (PGL)/pheochromocytoma (PCC), suggests a recent study.

Researchers retrospectively examined 20 consecutive patients (aged 21 to 77 years; 13 men) with high somatostatin receptor (SSTR) expression treated with 177Lu-DOTA-octreotate, including nine who received radiosensitizing chemotherapy. There was a median 22 GBg (median 4 cycles) cumulative activity. They examined PPRT outcomes in these patients from two referral centres.

A total of 14 patients received treatment for uncontrolled hypertension and six for progressive or symptomatic metastatic disease or local recurrence.

Three months following PRRT, eight of 14 patients treated for hypertension needed lesser medication doses; five showed no change in antihypertension doses; and one was lost to follow-up. Of the patients, 86 percent had serum chromogranin-A reduction.

Thirty-six percent of the entire cohort had disease regression (29 percent partial and 7 percent minor response) on computed tomography, with stable results in 50 percent.  There were three patients with bony disease evaluable only on SSTR imaging (2 partial response and 1 stable).

There was a median 39 months of progression-free survival, but median overall survival was not achieved (5 deaths; median follow-up, 28 months) in the study. Four patients presented with grade 3 lymphopaenia, and two had grade 3 thrombocytopaenia. In addition, two patients had renal impairment, which was mainly driven by underlying disease processes.

“Because PRRT has logistic and radiation-safety advantages compared to 131I-MIBG therapy, further prospective evaluation is warranted,” researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
29 Nov 2017
Rapid onset opioids may allow for more effective treatment of breakthrough cancer pain as their pharmacokinetic profile closely mimics the pain’s time course
Christina Lau, 22 Oct 2015
A 21-gene expression assay can identify patients with early-stage breast cancer who can skip adjuvant chemotherapy without facing an increased risk of recurrence at 5 years.
Cathy Chow, PhD, 27 Aug 2015

HER2-positive breast cancer tends to be more aggressive, has worse patient prognosis, and responds less to treatment. A two-pronged approach to block the HER pathway via pertuzumab (Perjeta®, Roche), a first-in-class HER dimerization inhibitor, in combination with trastuzumab and chemotherapy, may offer more treatment options for HER2-positive metastatic breast cancer patients as well as those with early breast cancer. 

Saras Ramiya, 25 Oct 2017
The first patient-reported outcomes study on durvalumab treatment after chemoradiation in locally advanced non-small cell lung cancer (NSCLC) shows patients’ quality of life is similar to that of the patients who received placebo.